@article{bruera:inserm-00764322, TITLE = {{Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.}}, AUTHOR = {Bruera, Gemma and Cannita, Katia and Di Giacomo, Daniela and Lamy, Aude and Troncone, Giancarlo and Dal Mas, Antonella and Coletti, Gino and Fr{\'e}bourg, Thierry and Sabourin, Jean-Christophe and Tosi, Mario and Ficorella, Corrado and Ricevuto, Enrico}, URL = {https://inserm.hal.science/inserm-00764322}, JOURNAL = {{BMC Medicine}}, PUBLISHER = {{BioMed Central}}, VOLUME = {10}, NUMBER = {1}, PAGES = {135}, YEAR = {2012}, MONTH = Nov, DOI = {10.1186/1741-7015-10-135}, KEYWORDS = {disease extension ; intensive regimen ; KRAS mutations ; metastatic colorectal cancer ; triplet chemotherapy plus bevacizumab}, PDF = {https://inserm.hal.science/inserm-00764322/file/1741-7015-10-135.pdf}, HAL_ID = {inserm-00764322}, HAL_VERSION = {v1}, }